iBio, Inc. Common Stock Market Cap ($52.96 Million)
Market Cap & Net Worth: iBio, Inc. Common Stock (IBIO)
iBio, Inc. Common Stock market cap. iBio, Inc. Common Stock (NASDAQ:IBIO) has a market capitalization of $52.96 Million ($52.96 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #21488 globally and #4820 in its home market, demonstrating a 16.48% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying iBio, Inc. Common Stock's stock price $0.82 by its total outstanding shares 64307256 (64.31 Million). Also see IBIO cash flow metrics for how efficiently the company converts equity into cash flow.
iBio, Inc. Common Stock Market Cap History (2025–2026)
iBio, Inc. Common Stock market cap history from 2025 to 2026. Data shows growth from $124.11 Million to $51.45 Million (0.00% CAGR). Check latest iBio, Inc. Common Stock stock price today for real-time trading data and today's change.
iBio, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how iBio, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset growth rate of iBio, Inc. Common Stock to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
514.46x
iBio, Inc. Common Stock's market cap is 514.46 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2025 | $124.11 Million | $400.00K | -$18.38 Million | 310.28x | N/A |
| 2026 | $51.45 Million | $100.00K | -$33.04 Million | 514.46x | N/A |
Competitor Companies of IBIO by Market Capitalization
Companies near iBio, Inc. Common Stock in the global market cap rankings as of November 5, 2026. Also see iBio, Inc. Common Stock total assets for a full breakdown of the balance sheet.
Key companies related to iBio, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of iBio, Inc. Common Stock (2025–2026)
Market capitalization of iBio, Inc. Common Stock from 2025 to today. Between 2025 and today, iBio, Inc. Common Stock's market cap moved from $124.11 Million to $ 51.45 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $51.45 Million | -58.55% |
| 2025 | $124.11 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of iBio, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $52.96 Million USD |
| MoneyControl | $52.96 Million USD |
| MarketWatch | $52.96 Million USD |
| marketcap.company | $52.96 Million USD |
| Reuters | $52.96 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About iBio, Inc. Common Stock
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides a panel of optimized CD3 antibodies that can be paired with tumor-targeting antibodies to generate bispecific T-cell engagers; StableHu, an AI antibody-optimiz… Read more